Upload
ledat
View
228
Download
2
Embed Size (px)
Citation preview
Monitoring and Audit in Clinical Trials
Wednesday 31st August 2016
Anna Barnett
In Chesterfield
In today’s session
1. Monitoring: What is and why do we do it?
2. At Site Monitoring: How do we do it?
3. Audit: What is it and how is it different from monitoring?
Generally: Why these are important for you and what you can expect
Section 1
Monitoring: What is and why do we do it?
Attacked by a duck on the way to Stamford GP site
What is Monitoring?
Monitoring is one of several functions used to ensure the quality of clinical trials:
–Monitoring –Audit – Inspection – SOPs
View of Dundee on flight from Stansted
Quality Assurance
Monitor
Audit
Inspect
Quality Assurance
Monitor
Audit
Inspect
Ongoing operational quality control
Snapshot of trial status with completed CAPA
Regulatory review for compliance with UK SIs – routine or triggered
Monitoring is a legal requirement
• All clinical information shall be recorded, handled and stored in such a way that it can be accurately reported, interpreted and verified, while the confidentiality of records of the trial subjects remains protected.
• UK Statutory Instrument 2004/1031 (as amended), Schedule 1, Part 2, 9
• Subject to paragraph (5), the sponsor shall put and keep in
place arrangements for the purpose of ensuring that with regard to that trial the conditions and principles of good clinical practice are satisfied or adhered to.
• UK Statutory Instrument 2004/1031 (as amended), Regulation 28, (2)
Monitoring is defined in ICH GCP
“The act of overseeing the progress of a clinical trial, and ensuring that it is conducted, recorded, and reported in accordance with the protocol, SOPs, GCP and regulatory requirements”
(ICH GCP 1.38)
A common misconception is that only clinical trial monitors perform
monitoring
Various Monitoring formats
Oversight of a trial can be through various different formats including:
– Committees
– Trial Management Groups
– At site monitoring
– Remote/phone based monitoring
– Centralised monitoring/data review
All these different formats are considered to be forms of monitoring and thus the monitoring of a trial may
involve a large number of different staff
What activities comprise “central monitoring” of a clinical trial and
should they be documented? • Eg. GOVERNANCE: Any relevant/important communication or contact
relating to the conduct of the trial by the sponsor would be part of monitoring the trial and this oversight, be it telephone calls, emails or letters should be documented and must be retained and this would also demonstrate regular contact with the investigator(s).
• Eg. DATA MANAGEMENT: The investigator site will submit the clinical data CRFs either using eCRF or faxing/sending paper CRFs. Any generated evidence of central monitoring activities regarding this data must be retained, these could include reports generated from interrogating the database, for example, looking at data submission timeliness, audit trails of the eCRF to examine times of completion, data query rates and response timeliness, SAE reporting rate, comparisons/reconciliations with other databases (e.g. IVRS, Central Labs) and data from other sites.
There should be a formal process for dealing with issues and data queries identified during central monitoring and data management activities, including an escalation process.
Risk assessment is used to determine the type and frequency of monitoring
• Trial specific to assess hazards: – Risks to participant safety from IMP – Risks to reliability of results – Risks from trial clinical procedures – Risk to patient rights: consent & protection of personal
data – Risks to compliance • Mitigate or accept risks (Risk Management Planning) • Use to develop the protocol and the OVERSIGHT &
MONITORING STRATEGY to manage risk
Section 2
At site monitoring: How do we do it?
Flight from Dundee
“At site” monitoring has 3 objectives
• To verify that the rights and well-being of human subjects are protected
• To ensure reported trial data are accurate, complete and verifiable from source data
• To ensure the trial is compliant with protocol, ICH GCP, regulatory requirements
Christmas market Birmingham
In practical terms this means...
• Monitors will look at: Informed consent Source data verification of your
CRF and SAE reports against the medical records
Ensure your TMF/ISF is appropriate and complete
Check other aspects of GCP such as the training and qualification of the staff
Ensure drug accountability has been carried out in accordance with Annex 13
In Lincoln, early morning
Monitoring (of all types) is an ongoing process throughout the duration of
the trial • Facilitates training and improvement
• Trial Managers and Clinical Trial Monitors see many different trials and will have valuable knowledge about how other trials or other sites in the same trial have solved problems etc – can provide valuable guidance and support to trial teams
The trial monitor and other staff are “on your side” to help you keep everything in shape and to reassure you
that you are conducting the trial well
At GP site, Edinburgh
Preparing for a monitoring visit
• 1. Agree the date and provide support with travel arrangements
• 2. Ensure access to electronic medical records and a computer from which to view
• 3. Make paper medical records available
• 4. Ensure TMF/ISF is up to date, review it beforehand
• 5. Book a room or quiet area of an office for the monitor to work
• 6. Welcome – this person may have had a long journey
Bugs: Common findings from at site monitoring visits
• Incorrect completion of consent forms
• Incomplete delegation & signature log
• TMF not up to date
• Incomplete documentation of Training
• CRF completion not sufficiently diligent
• Not scoring through, dating and initialling errors in the CRF
• Source data unsigned by the PI
Insect in Chesterfield
Outcome of “at site” and “remote” visits
• All “at site” and “remote” monitoring visits are reported
• Site staff are provided with a list of action points and are required to respond and sign off that they have completed the requested actions
The end of the line in Lowestoft
Expectations of the MHRA
• RESPONSE/REACTION: Results of centralised monitoring and “at site” monitoring visits should be effectively utilised to guide the management of the trial
• ADAPTATION: Trials with problems should receive increased monitoring or increased oversight by other means
Everyone involved in the trial should take an interest in the monitoring findings and be responsive to the
recommendations
Please remember
• The paperwork for a trial must be able to stand in isolation to enable
– The complete reconstruction of the trial
– And to prove that the trial was conducted to ICH GCP and UK SIs
Accompanied monitoring visit: Is Darth Vader on the train?
• Therefore....
– Knowing that something was done is not enough
– If it’s not written down and filed, it never happened
If you are not accurately documenting what you are doing then you might as well not bother doing it
View from hotel, Wellingborough
Monitoring approach is evolving
High level of “at site monitoring” Risk-based site monitoring
Centralised monitoring and sponsor oversight
2001 2004 2009 2011 2012 2013 2016
CT Directive Implementation of CT Directive
FDA and EMA publish risk based approach
Transcelerate consortium
High cost Lower cost
“Adaptive” site monitoring
Centralised monitoring should be used to target “at site” monitoring
• Recognised flags: – Low data reliability – Slow data flow rate – High volume of missing data – Site compliance to protocol eg. to visit schedule – Disproportionate number of SAE reports – Disproportionate number of protocol deviations – Site staff change – Very high recruitment – High number of reports of technical issues/questions – Breaches/Serious breaches – Perceived risk
Targeted use of monitoring resource for efficiency and optimal benefit
Monitor sites, data, subjects and events that require more attention and focus
Challenges: Assessment Communication Resource Planning
Navigating the tube strike with low phone battery
Change direction
Section 3
Audit: What is it and how is it different from monitoring?
Audit process
‘A systematic and independent examination of trial-related activities and documents to determine whether the evaluated trial-related activities were conducted, and the data recorded , analysed and accurately reported according to the protocol, Sponsor’s SOPs, GCP and the applicable regulatory requirements’
(ICH GCP 1.6)
Audit is a time defined exercise to bring a trial into a GCP compliant
status
Audit can be used • On a regular basis in a trial as a “second check” in addition to
monitoring
• As a remedial exercise for problem sites
• At the end of trial to ensure the trial can be archived with confidence
Why is my trial being audited?
• 1. Routine mid point audit
• 2. Trial has ended – final audit
• 3. Monitoring has revealed a compliance problem
• 4. Inspection by the regulatory agency is scheduled
What does the auditor wish to see?
• Compliance with SOPs, policies & regulations
• High quality research
• Safety obligations met
Process and Follow up • Audit of study by:
- reviewing all essential documents and processes
- staff interaction at open and close
• Producing an audit report that:
- documents findings
- may recommend corrective actions
The auditor expects to resolve all findings as quickly as possible
Comparison: Monitoring vs Audit Aspect Monitoring Audit
Perspective Overseeing progress Assesses historical progress and reviews related systems
Communication Ongoing relationship One off – set up of audit and performance feedback, CAPA
Training Responsibility Not a responsibility but may be an outcome of audit
Site facility review All aspects reviewed on ongoing basis Assesses during audit
Site electronic systems Ongoing review Review of key systems at point of audit
SDV Yes Reviews sample and process itself
Consent Reviews 100% Reviews, % varies
IMP Verifying all IMP appropriately supplied to site, handled, stored, accounted for and returned/destroyed.
Opportunity to review at global, site and subject level, on sample basis.
Adverse events Determining whether all adverse events occurring at the site are appropriately reported, within required timeframes.
Review on sample basis, sample biased to include SAEs when they occur.
Issues To identify and ensure resolution of all site issues.
To highlight issues and advise on process improvement.
Conclusion
• Clinical trials can be monitored, audited and inspected at any time – be ready
• Good, structured documentation is key (TMF = Three Messy Folders?)
• Monitors are here to help – please contact us! (We never agree
with you about a shortcut or bypass of a process though)